Meet our portfolio

Best-in-class Immune regulator in Ulcerative Colitis

Targeting Tumor-promoting Macrophages

Targeting Memory T-cells in Autoimmunity

Novel Bispecific Platform for Complement Engagement

SynOx Therapeutics Ltd was founded in November 2020 and is solely focused on developing emactuzumab, a best-in-class monoclonal antibody against CSF-1R, for the treatment of tenosynovial giant cell tumours (TGCT) and other macrophage-driven pathologies. SynOx is led by an experienced team of industry professionals with a successful track record of developing and bringing products to commercialisation.

Bicara Therapeutics is a clinical-stage biotechnology company developing dual-action biologics designed to modulate the tumor microenvironment to elicit a potent and durable anti-tumor response.

Tridek-One is developing a novel CD31 agonist approach to modulate immune activation for the treatment of autoimmune diseases.

Egle Therapeutics has been founded with a vision to become a game changer in the field of immunomodulating T-regulatory cells (Tregs) through the unique concept of Tregs’ starving while specifically targeting the most immunosuppressive ones.

Enhanc3D Genomics is a functional genomics company that has developed a proprietary disruptive technology to profile three-dimensional genome folding at high resolution.
Understanding DNA organization and long-distance interactions allows to link gene enhancers and non-coding genetic variants to their target genes.
Enhanc3D Genomics has a mission to be a first in class high precision navigator of the non-coding regions of the genome hereby unlocking novel disease-related targets.

Anavo’s mission is to pioneer systematic drug discovery and development approaches aimed at phosphatases, a rich and largely untapped therapeutic target class. Anavo’s approach focuses on combining profound understanding of phosphatase biology with deep drug discovery expertise and state-of-the-art technologies to design first-in- class and best-in-class small molecule modulators of phosphatase activity.

Primmune Therapeutics is harnessing the power of the innate immune system to develop small molecule, orally administered toll-like receptor 7 (TLR7) agonists as immunotherapies for the treatment of cancer and viral diseases.